BioSpace News Archive

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced the closing of a registered direct offering of 1,351,350 Class A ordinary shares at a per share offering price of $7.40.

L2P Research LLC, a leading preclinical CRO, today announced that it had completed its acquisition of METIS Research Laboratories headquartered in Ronkonkoma, New York.

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two conferences in March, 2020.

Today, the nationally recognized attorneys from Baron & Budd obtained an $11,850,000 settlement in a case against pharmaceutical marketing company, Sanofi-Aventis U.S., LLC. The company markets drugs, including Lemtrada, a treatment for patients with multiple sclerosis (MS).

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Officer, will provide a corporate overview at the Cowen and Company 40th Annual Healthcare Conference on March 2, 2020 at the Boston Marriott Copley Place.

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief.

Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2019.

With the surging demand for sample collection kits for diagnosing COVID-19 and other upper respiratory tract pathogens, COPAN is concentrating its efforts on strategic items to maximize product output and supply during the ongoing surge in demand due to the novel Coronavirus outbreak.